MRNA stock drags rivals after delay for COVID vaccine deliveries to EU (NASDAQ:MRNA)
seekingalpha.com
finance
2022-06-02 17:07:51

Joe Raedle/Getty Images News Moderna (NASDAQ:MRNA) is leading a modest selloff among U.S. COVID-19 vaccine makers on Thursday after the company announced an agreement with the European Commission (EC) to delay vaccine shipments scheduled for the current quarter. The amendment to the initial delivery schedule allows the member states to receive an updated version of the vaccine subject to approval by the European Medicines Agency (EMA), the company said. All three COVID-19 vaccine makers in the U.
